Safety of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers
Sign Up to like & getrecommendations! Published in 2022 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.00935-22
Abstract: This phase I study evaluated the safety of the optimal ceftazidime-avibactam (CZA) with aztreonam (ATM) regimens identified in hollow fiber infection models of MBL-producing Enterobacterales. Eligible healthy subjects aged 18 to 45 years were assigned to… read more here.
Keywords: approved dose; cza atm; cza; atm every ... See more keywords
Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilus
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-789
Abstract: Background: Luspatercept is an erythroid-maturation agent approved to treat anemia in patients (pts) with transfusion-dependent (TD) lower-risk myelodysplastic syndromes (LR-MDS) who are erythropoiesis-stimulating agent (ESA)–naive or –exposed. Luspatercept improved red blood cell (RBC) transfusion independence… read more here.
Keywords: pts treatment; approved dose; treatment; maximum approved ... See more keywords